# A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)

> **NCT01296971** · PHASE3 · WITHDRAWN · sponsor: **Hoffmann-La Roche**

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** peginterferon alfa-2a [Pegasys]
- **DRUG:** ribavirin [Copegus]
- **DRUG:** ribavirin [Copegus]

## Key facts

- **NCT ID:** NCT01296971
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-12
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** study was not started due to an administrative reason on the part of the local Health Authority
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01296971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01296971, "A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01296971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*